MannKind (MNKD) Reports Break-Even Earnings for Q2

This quarterly report represents an earnings surprise of -100.00%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.03 per share when it actually produced earnings of $0.04, delivering a surprise of +33.33%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. MannKind, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $76.53 million for the quarter ended June 2025, missing the Zacks Cons ...